ABEO vs LLY

Abeona Therapeutics maintains high 10x potential, primarily driven by its first-in-class FDA-approved gene therapy, ZEVASKYN, for the ultra-rare RDEB, establishing a significant regulatory moat in a market with critical unmet needs. The substantial cash position of $191.4M provides a crucial runway for commercialization. While Q4 2025 results confirmed a slow commercial ramp ($5.4M revenue miss, $...

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...